Vertex Pharmaceuticals, headquartered in Boston, specializes in developing small molecule drugs for serious diseases, with four approved cystic fibrosis treatments and therapies for sickle cell disease. The company employs 5,400 people and explores innovative treatments for various conditions, including type 1 diabetes.
David Altshuler sold 3,231 shares of VRTX on 13 March at $510.00 per share, worth a total of $1.6M. They now own 23,281 VRTX shares, or a 12% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
